3+ day, 4+ hour ago   (424+ words) Etcamah is a once-daily pill that breaks down the estrogen receptor many breast cancers use to grow and is already approved for a narrower group of breast cancer patients. The setback lands on a pipeline already under scrutiny. Shares of…...

4+ day, 17+ hour ago   (378+ words) Full-Life Wins U.S. and Australian Green Lights for First-in-Human FL-261 Lung Cancer Trial TipRanks Full-Life Wins U.S. and Australian Green Lights for First-in-Human FL-261 Lung Cancer Trial New updates have been reported about Full-Life Technologies. Full-Life Technologies has secured key regulatory clearances…...

5+ day, 13+ hour ago   (78+ words) TradingView IDYA: Darovasertib and key pipeline assets advance toward major regulatory and clinical milestones Darovasertib is nearing NDA completion with a potential U.S. launch in the first half of next year, supported by positive regulatory interactions and strong market opportunity. Key…...

1+ week, 26+ min ago   (65+ words) openPR.com AI-based Clinical Trials Solution Provider Market 2026 | Poised for Innovation and Global Expansion through 2030 Press release from: meditechinsights Permanent link to this press release: You can edit or delete your press release AI-based Clinical Trials Solution Provider Market 2026 | Poised…...

1+ week, 34+ min ago   (125+ words) Over the past decade, both biotech and pharma have increasingly seen a tendency to research, fund and develop products that largely could be considered ‘variations on a theme’, or more particularly, a few, highly developed but low-risk areas of focus....

1+ week, 8+ hour ago   (412+ words) BiotechDispatch Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of…...

1+ week, 6+ day ago   (20+ words) WRMJ RADIO Javascript is required to view this panorama....

1+ week, 6+ day ago   (434+ words) Daré Bioscience received an NIH award of $908,000 to support DARE-PTB2's preclinical development for preventing preterm birth. DARE-PTB2 is an early-stage investigational program aimed at developing a therapeutic approach to prevent idiopathic preterm birth. Daré Bioscience has received approximately $908,000 from…...

2+ week, 4+ day ago   (147+ words) Revolution Medicines won FDA approval Wednesday for the pancreatic cancer treatment that once caused its stock to skyrocket. The post FDA Approves 'Unprecedented' Pancreatic Cancer Drug appeared first on Investor's Business Daily. BREAKING: Fed Inflation Data Puts Pressure On Warsh…...

2+ week, 6+ day ago   (72+ words) TradingView ISOFOL: Phase II of arfolitixorin study set to begin, with strong cash reserves and expanded clinical sites Clinical development of arfolitixorin advanced with phase Ib dose escalation completed and phase II initiation planned. Operating losses increased year-over-year, but cash…...